HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- As DCIS incidence increases, ‘no easy answers’ available to guide patient care
-
- PD-1 antibodies a ‘big leap forward’ for NSCLC Benjamin C. Creelan, MD
- Lawmakers introduce Cancer Drug Coverage Parity Act
- Drug cost debate must not detract from focus on value in cancer care John Sweetenham, MD, FRCP, FACP
- FDA approves Promacta for pediatric patients with chronic immune thrombocytopenia
- FDA grants orphan drug designation to GMI-1271 for AML
- FDA grants priority review to Keytruda for advanced NSCLC
- FDA to review Opdivo plus Yervoy for advanced melanoma
- Andexanet alfa reverses rivaroxaban-induced anticoagulation in phase 3 ANNEXA-R trial
-
- CMS releases new Medicare Part B reimbursement data
- Gene therapy superior to haploidentical HSCT for SCID-X1
- Hospital VTE surveillance fails to decrease rates after discharge
- Academy of hospice, palliative medicine presents lifetime achievement award
- ASH announces faculty development program participants
- Dana-Farber/Boston Children's named best children's hospital for cancer
- NCCN Foundation presents grants to six researchers
- Caprini model may help predict VTE risk after lung cancer resection
-
- Adjuvant chemotherapy improves survival for men with high-risk localized prostate cancer
- ASCO president: Patient-centered approach essential for treatment, research
- Bevacizumab combination improves PFS in advanced, recurrent endometrial cancer
- CheckMate 017: Nivolumab bests docetaxel in squamous NSCLC
- Chemotherapy-free triplet therapy appears safe, effective for B-cell malignancies
- Clinical trials, health information technology platform to test power of precision medicine
- Complete lymph node dissection does not improve survival after positive SLNB in melanoma
- Daratumumab appears safe, effective in heavily pretreated multiple myeloma
-
- Elective neck dissection improves survival in early-stage oral cancer
- Induction chemotherapy with docetaxel preserves larynx function in squamous cell carcinoma
- Intermittent ADT fails to reduce toxicity in metastatic prostate cancer
- Nivolumab shows promise for advanced hepatocellular carcinoma
- Nivolumab yields superior OS in NSCLC compared with docetaxel
- Novel agent may be effective in poor-prognosis metastatic prostate cancer
- Novel chemotherapy drug demonstrates activity in advanced breast cancer
- Post-hospital prophylaxis could reduce risk for venous thromboembolism, death after lung resection
-
- Post-pneumonectomy VTE screening presents path to reduce risks
- Rilotumumab fails to improve outcomes in MET-positive gastric cancer
- Risks of adjuvant WBRT may outweigh benefits for limited brain metastases
- Sodium thiosulphate does not reduce cisplatin efficacy in standard-risk hepatoblastoma
- Sub-stage specific surveillance imaging detects relapses in melanoma